secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001493152-24-030682
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics' concussion drug ONP-002 passes FDA cardiotoxicity test, Phase II planned
--------------------------------------------------------------------------------

- ONP-002 showed no cardiotoxicity in GLP hERG study conducted by Charles River Laboratories.
- Inhibitory concentration >10 µM; large cardiac safety margin based on Phase I plasma levels.
- Phase II trial planning underway to evaluate ONP-002 in concussed patients.
- Concussion market estimated at 69M cases globally; annual US healthcare cost for TBIs exceeds $40.6B.
- ONP-002 is an intranasal neurosteroid new chemical entity targeting mild traumatic brain injury.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224030682/0001493152-24-030682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224030682/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer